News Release 

Greater prostate cancer incidence; mortality among Black men linked to genetic alterations

American Association for Cancer Research

Research News

Bottom Line: Prostate cancer tumors from African American men had higher frequencies of certain genetic alterations that may be associated with aggressive disease, compared with prostate cancer tumors from white men.

Journal in Which the Study was Published: Molecular Cancer Research, a journal of the American Association for Cancer Research

Author: Jianfeng Xu, DrPH, Vice President of Translational Research at NorthShore University HealthSystem and senior author of the study

Background: "Prostate cancer incidence and mortality are highest in African American men, but the exact reasons for the disparity are not fully understood," said Xu. "The disparity is likely due to multiple factors, including socioeconomic differences and biology. We suspect that differences in the genetic changes that occur within tumors may play a critical role."

How the Study was Conducted and Results: In this study, Xu, together with first author Wennuan Liu, PhD, and colleagues, sequenced 39 genes of interest in tumors and matched normal tissue from 77 African American patients with prostate cancer. They found that over 35 percent of these patients' tumors harbored potentially damaging mutations in several genes, including the DNA repair genes ATM, BRCA2, and ZMYM3, among other genes. ZMYM3, which regulates chromatin and DNA repair, was found to be among the most frequently mutated genes in these patients. Nine of the 77 African American patients (11.7 percent) had tumors harboring mutations in ZMYM3, compared to 2.7 percent of tumors from 410 white patients whose data were included in the Genomic Data Commons database.

In addition, Xu and colleagues examined whether there were differences in the copy number alterations --when genetic material is gained or lost--between the prostate tumors of African American and white patients. The researchers pooled data representing 171 African American patients and 860 white patients from several public databases. They found distinct copy number alterations between African American and white patients in the more aggressive, high-grade prostate tumors (Gleason score 7 or higher), but not in low-grade tumors. High-grade tumors from African American patients were more likely to have additional copies of the MYC oncogene and deletions of the LRP1B, MAP3K7, BNIP3L, and RB1 genes than tumors from white patients. Gain of MYC and loss of MAP3K7 or RB1 were also associated with more advanced tumor stage.

Author's Comments: "Our findings suggest that distinct genetic alterations in the prostate cancers of African American men, in comparison to white men, may contribute to more aggressive prostate cancer and could lead to a higher mortality rate," said Xu. "If confirmed in other studies, these results will not only help to understand the racial disparity of prostate cancer but could also help guide personalized clinical management, such as predicting prognosis and guiding targeted therapy."

Future work from Xu and colleagues will aim to understand how genetic alterations in African American men affect recurrence, metastasis, treatment, and prostate cancer-specific death. In addition, they are interested in developing tests to detect such genetic changes.

Study Limitations: Limitations of the study include the small sample size, the use of different platforms to generate genetic data, and technical differences in how sequencing was performed between samples from African American men in this study and those from white men in the Genomic Data Commons database.

###

Funding & Disclosures: The study was supported by grants from the United States Department of Defense, the Department of Defense Prostate Cancer Research Program, and the Prostate Cancer Biorepository Network. Xu declares no conflicts of interest.

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes 47,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 127 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops--the largest of which is the AACR Annual Meeting, with more than 100,000 attendees for the 2020 virtual meetings and more than 22,500 attendees for past in-person meetings. In addition, the AACR publishes nine prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.

To interview Jianfeng Xu, please contact Richard Lobb at richard.lobb@aacr.org or 215-906-3322.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.